The primary object of the conditioning regimen for allogeneic reduced-intensity stem cell transplantation (RIST) is immunosuppression to achieve stable engraftment of donor cells, rather than bone marrow ablation. Therefore, immune reconstitution after RIST might be different from that after conventional stem cell transplantation (CST). In this study, 22 patients underwent RIST and 28 underwent CST. The RIST regimen consisted of cladribine (2-CdA; 0.11 mg/kg/day for 6 days), BU (4 mg/ kg/day for 2 days), and rabbit anti-thymocyte globulin (ATG; 2.5 mg/kg/day for 2-4 days). The CST group received either the BU (4 mg/kg/day Â 4 days)/CY (60 mg/kg/day Â 2 days) (n ¼ 13) or CY (60 mg/kg/ day Â 2 days)/TBI (4 Gy/day Â 3 days) regimen (n ¼ 15). All patients underwent transplantation with G-CSFmobilized blood stem cells. Engraftment speed after RIST was fast and seven of 22 patients did not require platelet transfusion. We noted that the numbers of CD4+, CD4+CD45RA+, and CD4+CD45RO+ T cells after transplant in the RIST group were significantly lower than those in the CST group (P ¼ 0.0001 for both the comparisons). However, the reconstitution of CD20+ B cells was faster in the RIST group (P ¼ 0.0001). The response of T cells to PHA stimulation was lower in the RIST group (P ¼ 0.0001 on day 30 and P ¼ 0.02 on day 90). Nevertheless, there were no significant differences in the incidence of bacterial, fungal, or viral infections between the two groups. We concluded that our RIST regimen might delay laboratory-evaluated T-cell immune reconstitution compared to CST; however, the observed setbacks did not directly translate into clinically significant increases in infectious episodes.
Summary:
The primary object of the conditioning regimen for allogeneic reduced-intensity stem cell transplantation (RIST) is immunosuppression to achieve stable engraftment of donor cells, rather than bone marrow ablation. Therefore, immune reconstitution after RIST might be different from that after conventional stem cell transplantation (CST). In this study, 22 patients underwent RIST and 28 underwent CST. The RIST regimen consisted of cladribine (2-CdA; 0.11 mg/kg/day for 6 days), BU (4 mg/ kg/day for 2 days), and rabbit anti-thymocyte globulin (ATG; 2.5 mg/kg/day for 2-4 days). The CST group received either the BU (4 mg/kg/day Â 4 days)/CY (60 mg/kg/day Â 2 days) (n ¼ 13) or CY (60 mg/kg/ day Â 2 days)/TBI (4 Gy/day Â 3 days) regimen (n ¼ 15). All patients underwent transplantation with G-CSFmobilized blood stem cells. Engraftment speed after RIST was fast and seven of 22 patients did not require platelet transfusion. We noted that the numbers of CD4+, CD4+CD45RA+, and CD4+CD45RO+ T cells after transplant in the RIST group were significantly lower than those in the CST group (P ¼ 0.0001 for both the comparisons). However, the reconstitution of CD20+ B cells was faster in the RIST group (P ¼ 0.0001). The response of T cells to PHA stimulation was lower in the RIST group (P ¼ 0.0001 on day 30 and P ¼ 0.02 on day 90). Nevertheless, there were no significant differences in the incidence of bacterial, fungal, or viral infections between the two groups. We concluded that our RIST regimen might delay laboratory-evaluated T-cell immune reconstitution compared to CST; however, the observed setbacks did not directly translate into clinically significant increases in infectious episodes. Allogeneic hematopoietic stem cell transplantation (HSCT) has been shown to be potentially curative for patients with a variety of diseases including hematological malignancies, aplastic anemia, and immunodeficiencies. However, patients undergoing HSCT experience a prolonged period of immunodeficiency due to complete destruction of the host immune system, resulting in the potentiation of infectious complications. The immune reconstitution of lymphoid and myeloid cells, as well as their subsets, after various types of transplants has been described. [1] [2] [3] [4] [5] [6] The source of hematopoietic stem cells appears to influence rate of immunohematological recovery after HSCT. Allogeneic PBSC represent a new source of hematopoietic progenitor cells, and are being increasingly used for transplantation. Recent clinical studies have shown more rapid recovery of neutrophil, platelet count, and immune reconstitution after PBSC transplantation (PBSCT) compared to BMT.
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1,2 On the other hand, the application of CD34+ cell selection or T-cell depletion to prevent graft-versus-host disease (GVHD) has resulted in the delay of immune reconstitution and functional abnormalities. 5, 6 Recently, reduced-intensity conditioning regimens containing purine analogs have been increasingly used to reduce regimen-related toxicities (RRT). 8 The primary object of reduced-intensity stem cell transplantation (RIST) is immunosuppression to aid engraftment of donor cells that carry the potential to induce graftversus-leukemia/tumor effects. Therefore, immune reconstitution after RIST might be different from that after conventional stem cell transplantation (CST). To clarify this, we prospectively compared immune reconstitution after RIST and CST by evaluating the number of lymphocyte subsets and the response to lymphocyte stimulation tests.
Materials and methods

Patients and conditioning regimens
Between July 1999 and October 2000, 22 patients received RIST in the National Cancer Center Hospital in Tokyo, Japan, for treatment of hematological malignancies, severe aplastic anemia (SAA), and refractory solid tumors. The protocol was approved by the institutional review board (IRB). There were 15 male and 7 female patients with a median age of 41.5 (range, 15-66). Underlying diseases included hematological (n ¼ 14) and solid malignancies (n ¼ 6), SAA (n ¼ 1), and paroxysmal nocturnal hemoglobinuria (PNH; n ¼ 1). The RIST regimen consisted of cladribine (2-CdA; 0.11 mg/kg/day for 6 days, total dose 0.66 mg/kg), BU (4 mg/kg/day for 2 days, total dose 8 mg/ kg), and rabbit anti-thymocyte globulin (ATG; 2.5 mg/kg/ day for 2-4 days, total dose 5-10 mg/kg). 9 Seven patients received ATG for 4 days while, beginning in April 2000, 15 received ATG for 2 days after stable engraftment was confirmed with four doses of ATG. We evaluated the time to engraftment, the incidences of infections, acute GVHD (aGVHD), and immune reconstitution in comparison to control data observed in 28 patients with hematological malignancies who received CST during the same period. The CST regimen consisted of BU (4 mg/kg/day for 4 days, total dose 16 mg/kg)/CY (60 mg/kg/day for 2 days, total dose 120 mg/kg) (n ¼ 13) or CY (60 mg/kg/day for 2 days)/ TBI (4 Gy/day for 3 days) (n ¼ 15). All patients in the CST group had hematological malignancies. Patient characteristics are shown in Table 1 .
Donors and grafts
All donors were HLA-identical or one antigen-mismatched related donors. PBSC were mobilized with human recombinant G-CSF 10 mg/kg/day, and leukapheresis was started on day 4. All apheresis procedures were performed using a continuous-flow blood cell separator (COBE BCT, Lakewood, CO, USA). Leukapheresis was repeated until a minimum yield of 2.0 Â 10 6 CD34+ cells/kg of recipient body weight was achieved. Leukapheresis-collected cells were slowly mixed with an equal volume of freezing solution to give final concentrations of 10% dimethyl sulfoxide and up to 2 Â 10 8 cells/ml. The cells were frozen using a Cryo-Med programmed freezer (Forma Scientific, Marietta, OH, USA) and stored in liquid nitrogen that maintained a temperature of À1961C. 
GVHD prophylaxis and supportive care
For GVHD prophylaxis, cyclosporin A (CsA, 3.0 mg/kg/ day by continuous intravenous infusion from day À1) alone was used in patients who received RIST, except for the first two patients who also received short-term i.v. Methotrexate (MTX, 10 mg/m 2 on day 1, 7 mg/m 2 on days 3 and 6). All patients in the CST group received the combination of CsA and short-term MTX. The dosage of CsA was adjusted to maintain the blood level between 250 and 400 ng/ml. Diagnosis of aGVHD was based upon histopathological confirmation, except for liver GVHD.
For patients at high risk of relapse without signs of aGVHD by day 35, we started to taper the dose of CsA by 5-10% weekly. CsA was discontinued by day 28 in three patients (one in RIST, two in CST) who had refractory leukemia at the time of transplant. Patients who developed Grades II-IV aGVHD received 1 or 2 mg/kg/day methylprednisolone. All of the patients received intravenous G-CSF 5 mg/kg/day from day 6 until the neutrophil counts recovered to greater than 1x10 9 /l. Antimicrobial prophylaxis consisted of ciprofloxacin 600 mg/day, fluconazole 200 mg/day, and acyclovir 1000 mg/day. All patients received intravenous immunoglobulin (anti-CMV hightiter) 5 g weekly until day 100.
Definition of infection
CMV infection was defined as a positive antigenemia assay and CMV diseases were defined as the demonstration of CMV by biopsy specimen, or CMV by PCR in bronchoalveolar fluid in presence of pulmonary infiltrates. The diagnosis of bacterial infection was based on the occurrence of at least one positive culture in the face of appropriate clinical findings, and fungal infections were defined as the demonstration of fungi by blood culture and/or biopsy specimen.
Immunophenotypic analysis
Immunophenotypic analyses were performed with flow cytometry, using a whole-blood lysis method on days 30, 60, 90, 120, 180, 240, 300, and 365 after SCT. Control data were obtained from healthy adult donors (n ¼ 12). Murine MoAbs of the IgG subclass were used to define background staining. The MoAbs used to detect T-cell antigens Anti-CD2/CD2R stimulation. The CD69 antigen is an integral membrane protein that is rapidly induced on the surface of activated lymphocytes. 10 The percentage of CD69 expression on freshly isolated cells and on cells stimulated (371C for 6 h) with 2 ml anti-CD2/CD2R (anti-T11 2 /anti-T11 3 , BD) was quantified by two-color flow cytometry on CD3+CD69+ T cells at days 30, 90, 180, and 365 after HSCT.
Statistical analysis
Time to engraftment and numbers of infused CD34+ or CD3+ cells were compared using Mann-Whitney U-tests for unpaired comparisons. Serial changes in immunological parameters were compared by repeated-measures analysis of variance (ANOVA) tests.
Results
Engraftment
There was no significant difference in the number of infused CD34+ or CD3+ cells between the two groups (P ¼ 0.08 and 0.40, respectively). All but two patients who received the RIST regimen achieved sustained engraftment. One patient had primary graft rejection after transplant from a one antigen-mismatched related donor, which was subsequently followed by autologous hematopoietic recovery. Another patient died of bacteremia before engraftment. Median time to neutrophil engraftment was 11 days (range, 0-14 days) in the RIST group and 14 days (11-22 days) in the CST group (P ¼ 0.0001). Median time to platelet engraftment was 8.5 days (0-12 days) in the RIST group and 14 days (9-26 days) in the CST group (P ¼ 0.0001)
Immune reconstitution following reduced-intensity transplantation T Saito et al (Table 1 ). All the patients in the CST group required platelet transfusions, whereas seven patients in the RIST group never required platelet transfusions.
Incidences of documented infections and acute GVHD
Seven patients (32%) in the RIST group developed bacterial and two (9%) developed fungal infection. On the other hand, in the CST group, 10 patients (36%) developed bacterial and one (4%) developed fungal infection. Ten (50%) in the RIST group and 18 (64%) in the CST group developed positive antigenemia, but none had CMV disease. There were no significant differences in the incidence of bacterial, fungal, or viral infections between the two groups. Grades II-IV aGVHD was observed in six (30%) in the RIST group and 11 (39%) in the CST group ( Table 1) . Figure 1 (a-g) shows recovery of CD3+, CD4+, and CD8+ T cells, the CD4/CD8 ratio, CD4+45RA+ and CD4+45RO+ T cells, and the RA/RO ratio after HSCT. The numbers of CD4+, CD4+CD45RA+, and CD4+CD45RO+ T cells were significantly lower in the RIST group than in the CST group (P ¼ 0.0001 each) (Figure 1b, e, f) . The CD4/CD8 ratio and RA/RO ratio in the RIST group were also lower than those in the CST group (P ¼ 0.0001 each) (Figure 1d, g ). However, there were no significant differences in the numbers of CD3+ and CD8+ T cells between the two groups (P ¼ 0.51 and 0.27, respectively) (Figure 1a, c) . Figure 1 (h, i) shows recovery of CD3-CD56+ NK cells and CD3+CD161+ NKT cells after HSCT. There was no significant difference in the numbers of CD56+ NK cells and CD161+ NKT cells between the two groups (P ¼ 0.42 and 0.31, respectively). There were also no significant differences in the numbers of CD57+ NK cells and Va24+ NKT cells between the two groups (data not shown) (P ¼ 0.12, 0.14, respectively).
Influence of the conditioning regimen on immune reconstitution
Figure 1(j) shows the recovery of CD20+ B cells after HSCT. The recovery of CD20+ B cells was significantly faster in the RIST group (P ¼ 0.0001).
Influence of the development of aGVHD on immune reconstitution
It has been reported that the development of aGVHD is also an important predictor of delayed immune reconstitution. 11 In this series, however, although the development of Grades II-IV acute GVHD affected the recovery of CD3+ and CD8+ T cells (P ¼ 0.003) (Figure 2a, c) , it did not affect that of CD4+, CD4+CD45RA+, and CD4+ CD45RO+ T cells (Figure 2b, d, e) . It also did not affect the recovery of CD3-56+ NK cells and CD3+CD161+ NKT cells (Figure 2f, g ). On the other hand, the recovery of CD20+ B cells was delayed in patients who developed Grades II-IV aGVHD compared to those who did not (P ¼ 0.0002) (Figure 2h ). Figure 3(a) shows the recovery of PHA stimulation after HSCT. The median (range) indices of PHA stimulation at days 30 and 90 after HSCT were 6 (1-47) and 35 (4-232) in the RIST group and 61 (5-235) and 132 (9-320) in the CST group, respectively. The responses of T cells to PHA stimulation on days 30 and 90 were also lower in the RIST group early after HSCT (P ¼ 0.0001, 0.02, respectively). On day 180, however, the response in RIST caught up with that in the CST group (P ¼ 0.72). Figure 3(b) shows CD2/ CD2R stimulation after HSCT. There was no difference in the response to CD2/CD2R stimulation between the two groups (P ¼ 0.72 on day 30, P ¼ 0.77 on day 90, respectively).
PHA and CD2/CD2R stimulation
Discussion
Although immune reconstitution after CST has been extensively studied, only a few published studies have analyzed immune reconstitution after RIST. 12, 13 In this study, we analyzed immune parameters in patients following RIST and compared the results with those in patients who underwent CST. The numbers of T-and NK cells transfused in PBSC grafts are several-fold higher than those in bone marrow, 1 resulting in rapid immune reconstitution after PBSCT. 2 After conventional PBSCT, the numbers of CD3+, CD8+, and CD4+CD45RO+ T cells normalized within 6 months. 3 On the other hand, T-cell depletion, either in vivo or in vitro, using ATG, 14 anti-CD6, 5 anti-CD52, 15 or CD34+ cell selection 6 has been associated with delayed immune reconstitution, with a persisting decrease in the percentage of CD4+, CD4+CD45RA+ T cells, and the CD4/CD8 ratio for longer than 1 year. 6 Recently, reduced-intensity conditioning regimens containing purine analogs have been increasingly used to reduce RRT. 7, 8 The primary target of RIST is intense immunosuppression to aid in the engraftment of donor cells. Therefore, these conditioning regimens occasionally contain ATG or anti-CD52. 16, 17 In this study we showed that the percentages of CD4+, CD4+CD45RA+ and CD4+CD45RO+ T cells, and the CD4/CD8 and RA/RO ratios were decreased after RIST using ATG compared to CST. Although the most important factor in inducing delayed immune reconstitution is the use of ATG in addition to purine analog, Morecki et al 13 reported earlier immune reconstitution in RIST using ATG and flurabine compared to CST. Hence, the possibility that use of 2-CdA, rather than flurabine, resulted in delayed recovery of the immune system should be considered. Several other factors, including the type of graft (bone marrow, peripheral blood, or cord blood), age of the recipient at transplant, and presence of GVHD, could affect immune reconstitution after transplant. 3, 4, 6, 11 In this study, however, PBSC was exclusively used as a stem cell source in both the groups, and there were no differences in the age of the recipient or the incidence of aGVHD. Although the RIST group included more HLA-mismatched transplants than the CST group (27 vs 11%, P ¼ 0.27), a delay in the recovery of CD4+, CD4+CD45RA+, and CD4+CD45RO+
T cells was also found in an analysis only in patients who underwent HLA-matched transplant (data not shown).
In this study, the greatest differences in immune recovery kinetics between the two groups were seen during the early post-transplant period. However, the findings in the RIST group caught up with those after CST on day 180, and the results in both groups had normalized after about 1 year. There is little information available on the correlation of viral, bacterial, and fungal infections with immune reconstitution after highly immunosuppressive regimens. Immune reconstitution following reduced-intensity transplantation T Saito et al
Although immune reconstitution were delayed compared to that in CST patients. The frequency of documented infections did not increase in patients who received RIST in the present study. This may be partly explained by less mucosal damage or a shorter period of granulocytopenia in the RIST group. NK cells have been shown to mediate several immunologic functions, including defense against the proliferation of tumor cells in animal models and in a clinical trial. 19, 20 In addition, NKT cells, defined as CD3+ CD161+ or CD3+Va24+ cells, are also considered to be important for an antileukemic effect. 21 The relationship between NK-or NKT-cell reconstitution after transplant and the incidence of infection, GVHD or relapse remains to be evaluated in further studies.
The CD2 molecule expressed on T-and NK cells is a type I transmembrane glycoprotein that is implicated in T-cell adhesion and activation. 22 Signaling through CD2 results in marked increases in CD69 expression on the T-cell Immune reconstitution following reduced-intensity transplantation T Saito et al surface and T-cell metabolism. 23 The CD69 antigen is an integral membrane protein that is rapidly induced on the surface of activated T-, NK-and B cells. 10 Therefore, the expression of CD69 on T cells after CD2/CD2R stimulation could be a marker for T-cell function. Our results indicated that the function of individual T cells in RIST was comparable to that in CST, although there were fewer T cells after RIST than after CST. This might have prevented the increase in clinically documented infections in RIST.
B-cell counts were higher during the first 12 months after RIST compared with CST, probably due to the omission of MTX from GVHD prophylaxis. 6 In addition, B-cell reconstitution was faster in patients without Grades II-IV aGVHD, independent of the type of transplant. It has been shown that GVHD and its treatment significantly delay immune reconstitution of CD4+ T cells and CD20+ B cells, 11 whereas the number of CD8+ T cells is increased.
In this study, we confirmed that CD3+ and CD8+ T cells were significantly higher in patients with Grades II-IV aGVHD than in those without aGVHD or with Grade I aGVHD. It is conceivable that such subsets of cells play an important role in the pathogenesis of aGVHD. In summary, we concluded that our RIST regimen with ATG might delay laboratory-evaluated T-cell immune reconstitution compared to CST, although the observed setbacks did not directly translate into clinically significant increases in infections. Immune reconstitution following reduced-intensity transplantation T Saito et al
